LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST - News) today reported results for the third quarter ended September 30, 2008. Cubist’s total net revenues from CUBICIN® (daptomycin for injection) increased 45% from the prior year, from $76.3 million in the third quarter of 2007 to $110.6 million in the third quarter of 2008. U.S. net product revenue from CUBICIN was $109.2 million. Total revenues for the third quarter of 2008 increased 41% over the third quarter of 2007 from $79.8 million in the third quarter of 2007 to $112.4 million in the third quarter of 2008. Included in total revenues for the third quarter of 2008 is $1.4 million of service revenue relating to Cubist’s exclusive agreement with AstraZeneca to sell and provide other support in the United States for MERREM® I.V. (meropenem for injection).
